Female carriers of BRCA1 or BRCA2 mutations have a lifetime risk of 49 to 87% for developing breast cancer [5], [6], wherefore they are offered intensive cancer surveillance as well as risk reducing surgery. This evidence concerns the gene BRCA2 and cancer.